Plethora Solutions

Plethora Solutions Holdings plc is a United Kingdom-based specialty pharmaceutical company. The Company is engaged in the development and commercialization of pharmaceutical treatments for premature ejaculation in the area of men's sexual health. The Company is engaged in the development of new pharmaceutical products, which it refers to as Plethora Development. The Company has developed PSD502, which is a treatment for premature ejaculation, and has also completed phase III clinical trials. The PSD502 is also authorized to be marketed under the name of Prilocaine Lidocaine Plethora through the European Medicines Agency (EMA). Its subsidiaries include Plethora Solutions Limited and Plethora Therapeutics Limited.

Type
Public
HQ
Chalgrove, GB
Size (employees)
5 (est)
Plethora Solutions is headquartered in Chalgrove, GB

Plethora Solutions Office Locations

Plethora Solutions has an office in Chalgrove
Chalgrove, GB (HQ)
Warpsgrove Ln

Plethora Solutions Data and Metrics

Plethora Solutions Financial Metrics

Plethora Solutions's revenue was reported to be £3.9 m in FY, 2014
GBP

Net income (FY, 2015)

(4.3 m)

Cash (31-Dec-2015)

91 k
GBPFY, 2013FY, 2014FY, 2015

Revenue

3.9 m

Pre tax profit

(1.5 m)(9.2 m)(4.5 m)

Net Income

(1.5 m)(9.2 m)(4.3 m)
GBPFY, 2013FY, 2014FY, 2015

Cash

608 k3.5 m91 k

Current Assets

641 k3.8 m519 k

PP&E

76 k60 k

Total Assets

641 k3.9 m579 k
GBPFY, 2014FY, 2015

Cash From Operating Activities

3 m(3.2 m)

Income Taxes Paid

195 k
Show all financial metrics

Traffic Overview of Plethora Solutions

Plethora Solutions Company Life and Culture

You may also be interested in